Time trends of drug-specific actionable adverse events among patients on androgen receptor antagonists: Implications for remote monitoring
Canadian Urological Association Journal2021Vol. 16(3), pp. E146–E149
Citations Over Time
Lauren Fleshner, Alejandro Berlín, Karen Hersey, Miran Kenk, Katherine Lajkosz, Susan Nguyen, Jacob Wise, Sophie O’Halloran
Abstract
Attaining AEs secondary to abiraterone/enzalutamide decreases over time and tends to occur within the first six months of therapy. Most actionable AEs can be remotely monitored. Given COVID-19, remote monitoring after six months of initiating abiraterone or enzalutamide appears appropriate.
Related Papers
- → AR aberrations and resistance to abiraterone or enzalutamide(2016)45 cited
- → Impact of metabolic syndrome on clinical outcome of castration resistant prostate cancer (CRPC) patients treated with abiraterone and enzalutamide(2017)1 cited
- → Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer(2019)1 cited
- Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.(2016)
- → Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases(2020)